Shree Ganesh Remedies Limited Stock

Equities

SGRL6

INE414Y01015

Biotechnology & Medical Research

Market Closed - Bombay S.E. 06:00:56 2024-06-21 EDT 5-day change 1st Jan Change
837.7 INR +0.84% Intraday chart for Shree Ganesh Remedies Limited -1.02% +22.70%

Financials

Sales 2022 713M 8.53M 11.69M Sales 2023 902M 10.8M 14.79M Capitalization 3.1B 37.08M 50.78M
Net income 2022 134M 1.6M 2.2M Net income 2023 170M 2.04M 2.79M EV / Sales 2022 4.94 x
Net cash position 2022 38.83M 465K 637K Net Debt 2023 224M 2.68M 3.67M EV / Sales 2023 3.68 x
P/E ratio 2022
26.6 x
P/E ratio 2023
18 x
Employees 110
Yield 2022
0.17%
Yield 2023
0.2%
Free-Float 17.84%
More Fundamentals * Assessed data
Dynamic Chart
Shree Ganesh Remedies Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Shree Ganesh Remedies Begins Trial Run of Plant in Gujarat, India MT
Shree Ganesh Remedies Limited Announces Company Secretary and Compliance Officer Changes CI
Shree Ganesh Remedies Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Shree Ganesh Remedies Limited Announces the Reconstitution of Committees and Resignation of Directors CI
Shree Ganesh Remedies Limited Announces Director Appointments CI
Shree Ganesh Remedies Limited Proposes Final Dividend for Financial Year 2022-23, Payable on 25 September, 2023 CI
Shree Ganesh Remedies Forms New Wholly-Owned Subsidiary in US MT
Shree Ganesh Remedies Limited Announces Intimation for Incorporation of Wholly Owned Subsidiary Company Named Sgrl Usa Inc in United States CI
Shree Ganesh Remedies Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Shree Ganesh Remedies Gets License to Manufatcure Drugs, Other Products in Gujarat, India MT
Shree Ganesh Remedies Limited Receives Receipt of FDA License CI
Shree Ganesh Remedies Limited Recommends Final Dividend for the Year Ended March 31, 2023 CI
Shree Ganesh Remedies Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Shree Ganesh Remedies Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
More news
1 day+0.84%
1 week-1.02%
Current month+36.80%
1 month+36.88%
3 months+25.24%
6 months+20.67%
Current year+22.70%
More quotes
1 week
807.65
Extreme 807.65
874.10
1 month
573.10
Extreme 573.1
934.95
Current year
557.95
Extreme 557.95
934.95
1 year
380.00
Extreme 380
934.95
3 years
213.20
Extreme 213.2
934.95
5 years
42.96
Extreme 42.9597
934.95
10 years
22.23
Extreme 22.227
934.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 95-04-26
Director of Finance/CFO - 21-01-17
Comptroller/Controller/Auditor - 17-07-18
Members of the board TitleAgeSince
Chief Executive Officer 68 95-04-26
Director/Board Member 34 17-07-28
Director/Board Member 33 17-10-10
More insiders
Date Price Change Volume
24-06-21 837.7 +0.84% 4,135
24-06-20 830.7 +0.28% 3,321
24-06-19 828.4 +1.27% 4,628
24-06-18 818 -3.35% 12,249
24-06-14 846.4 -1.72% 5,075

Delayed Quote Bombay S.E., June 21, 2024 at 06:00 am

More quotes
Shree Ganesh Remedies Limited is an India-based company, which is engaged in the business of bulk drug intermediates. The Company is a supplier of pharmaceutical intermediates and specialty chemicals with chlorination, Grignard reaction, hydrogenation, and high-vacuum distillation. The Company's products include intermediates by active pharmaceutical ingredient (API), and fine and specialty chemicals. It offers services, including customized chemistry and manufacturing, assets and infrastructure and key technologies and expertise. It offers its solutions to the markets, such as life sciences: human health and veterinary, flavor and fragrance, polymer industries, electronics, and agro chemicals. The Company has a portfolio of approximately 39 drug intermediates, and 18 specialty chemical products. It also delivers a service of contract manufacturing for chemical reactions like amination, amidation, alkylation, bromination, catalytic hydrogenation and chlorination.
More about the company